Network officials also said voters should expect more of a Koch focus on grassroots activism throughout the 2020 election cycle.Politicsread more
GM's usage of temporary workers, potential closure of plants and health care contributions remain major sticking points, according to people familiar with the talks.Autosread more
AT&T isn't focused on selling or divesting DirecTV, despite pressure from stakeholder Elliott Management, sources tell CNBC.Technologyread more
The measure to keep the government running through Nov. 21 now heads to the Senate, where McConnell has signaled he will back a temporary spending plan.Politicsread more
Amazon's purchase comes as part of its plan to convert its delivery fleet to 100% renewable energy by 2030. The e-commerce retailer already runs 40% of its fleet on renewable...Autosread more
American Airlines struggled with flight delays and cancellations this summer, hamstrung by the grounded Boeing 737 Max and mired in a bitter labor dispute with its mechanics.Airlinesread more
Apple's iOS 13.1 will be released on Sept. 24, six days earlier than previously announced.Technologyread more
Stripe, a payments company, announced an additional $250 million funding round on Thursday, bringing its valuation to $35 billion.CNBC Disruptor 50read more
May 28 (Reuters) - Allergan Plc said on Tuesday it will voluntarily recall its textured breast implants from the Canadian market, after the country's health regulator suspended the company's licenses for its Biocell implants, citing increased risk of cancer.
Any unused Biocell saline-filled and silicone-filled textured breast implants will be removed from the Canadian market and no longer be sold, the drugmaker said.
The recall does not impact its Natrelle smooth implants, Allergan said, adding it would explore options to appeal Health Canada's decision to suspend the licenses.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Sriraj Kalluvila)